A Message from Smallcaps Daily 
This first-in-class biotechnology company with the world’s ONLY fully human anti-CD3 monoclonal antibody in clinical development should be high on your radar! There is currently still no cure for neurodegenerative diseases such as Alzheimer's, MS, and ALS. The rise in diagnoses can be attributed to the aging population as life expectancy increases. Not only is this a growing health concern, but the annual cost to the US from Alzheimer’s disease and related dementias and other neurodegenerative diseases is tremendous. It was $655 billion in 2020! Now more than ever we need treatments to fight these terrible diseases. One underfollowed NASDAQ company in the biotech space is uniquely standing out as it focuses on developing drugs with a unique approach for these rising diseases. This clinical-stage biotechnology company specializes in developing transformative therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, Crohn's Disease and KRAS NSCLC. The company’s “wonder drug” is the world’s only fully human anti-CD3 monoclonal antibody in clinical development! Activated T cells play an important role in the inflammatory process. The company’s drug binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. With its revolutionary approach to attacking neurodegenerative and lung diseases, this company has the potential to change the way immunotherapies are currently conducted and may be a promising gem hiding in the biotech arena. Learn More to See How This Undiscovered Biotech Has Blockbuster Potential With The Only Fully Human Anti-CD3 Monoclonal Antibody In Clinical Development! | 
No comments:
Post a Comment